Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality

Stroke

Volumn 39, Issue 10, 2008, Pages 2824-2829

  MacLeod, Malcolm R ^a   Van Der Worp, H Bart ^b   Sena, Emily S ^a,c   Howells, David W ^c   Dirnagl, Ulrich ^d   Donnan, Geoffrey A ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Neuroprotection; NXY 059; Study quality

Indexed keywords

DISUFENTON SODIUM; BENZENESULFONIC ACID DERIVATIVE; CARDIOVASCULAR AGENT;

ARTICLE; BRAIN ISCHEMIA; DRUG EFFICACY; EXPERIMENTAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; SYSTEMATIC REVIEW; ANIMAL; CLINICAL TRIAL; EPIDEMIOLOGY; META ANALYSIS; METHODOLOGY; STANDARD;

ANIMALS; BENZENESULFONATES; BIAS (EPIDEMIOLOGY); BRAIN ISCHEMIA; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 54049103993     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.515957     Document Type: Article

References (30)

1. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
2. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
3. Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development. Stroke. 1999;30:2752-2758.
4. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478.
5. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007; 30:433-439.
6. Green AR. Pharmacological approaches to acute ischaemic stroke: reper-fusion certainly, neuroprotection possibly. Br J Pharmacol. 2008; 153(suppl 1):S325-338.
7. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28:217-219.
8. Proctor PH, Tamborello LP. SAINT-I worked, but the neuroprotectant is not NXY-059. Stroke. 2007;38:e109.
9. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20-25.
10. Sena E, Wheble P, Sandercock P, Macleod M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke. 2007;38:388-394.
11. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35:1203-1208.
12. Lapchak PA, Song DH, Wei JD, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol. 2004;188:279-285.
13. Lapchak PA, Araujo DM, Song DH, Wei JD, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model - combination studies with the thrombolytic tissue plasmin-ogen activator. Stroke. 2002;33:1411-1415.
14. Balogh GT, Vukics K, Konczol A, Kis-Varga A, Gere A, Fischer J. Nitrone derivatives of Trolox as neuroprotective agents. Bioorganic & Medicinal Chemistry Letters. 2005;15:3012-3015.
15. Samaranayake S. Study quality in experimental stroke. 2006. CAMARADES Monograph No 2. Available at: www.camarades.info/ index-files/CM2.pdf. Accessed January 24, 2008.
16. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, Bath PMW, Macleod M, Dirnagl U. Empirical evidence of bias in the design of experimental stroke studies. A metaepidemiologic approach. Stroke. 2008;39:929-934.
17. Wu Q. Combining the evidence from different drug trials. 2006. CAMARADES Monograph No 1. Available at: www.camarades.info/ index-files/ CAMARADES%20Monograph%201.pdf. Accessed February 6, 2008.
18. Tureyen K, Vemuganti R, Sailor KA, Dempsey RJ. Infarct volume quantification in mouse focal cerebral ischemia: a comparison of triphe-nyltetrazolium chloride and cresyl violet staining techniques. J Neurosci Methods. 2004;139:203-207.
19. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, Harsing LG Jr, Matyus P, Szenasi G, Albert M. Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. Brain Res. 2006;1116:159-165.
20. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334:197-199.
21. van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain. 2007;130:3063-3074.
22. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res. 2005;38:35-41.
23. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:778-787.
24. Lapchak PA, Araujo DM, Song DH, Wei JD, Purdy R, Zivin JA. Effects of the spin trap agent disodium (tert-butylimino)methyllbenzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model combination studies with tissue plasminogen activator. Stroke. 2002;33:1665-1670.
25. Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003;34:2228-2233.
26. Marshall JWB, Duffin KJ, Green AR, Ridley RR. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001;32: 190-197.
27. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 2002;135:103-112.
28. Yoshimoto T, Kanakaraj P, Ying MJ, Cheng M, Kerr I, Malaiyandi L, Watson JA, Siesjo BK, Maples KR. NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res. 2002;947:191-198.
29. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjo BK. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res. 2002;932:99-109.
30. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res. 2001;909:46-50.